Posts By: Michelle Weber

UCB Announces U.S. FDA Approval of RYSTIGGO[®] (rozanolixizumab-noli) for the Treatment of Adults with Generalized Myasthenia Gravis What you need to know: This is a new therapy that is designed as a monoclonal antibody that binds to the neonatal Fc receptor (FcRN). The delivery of this therapy is subcutaneous injection – so it’s quicker and… Read more »